Table 4.
Cox Regressions of Survival by Anti-viral IgG Seropositivity, for Patients With or Without Reported Dexamethasone Usage at Time of Blood Draw, San Francisco Bay Area Adult Glioma Study
| Received Dexamethasone | No Dexamethasone Reported | |||||||
|---|---|---|---|---|---|---|---|---|
| n Cases | n Died | Median Months Survival | P, HR | n Cases | n Died | Median Months Survival | P, HR | |
| (95% CI) a | ||||||||
| (95% CI) a | ||||||||
| IgG for VZV | 469 | 434 | .046 0.67 (0.45–0.99) |
889 | 622 | .13 0.76 (0.54–1.08) |
||
| Negative | 30 | 29 | 11.3 | 48 | 34 | 50.5 | ||
| Positive | 439 | 405 | 15.4 | 841 | 588 | 49.6 | ||
| IgG for CMV | 284 | 265 | .17 1.2 (0.92–1.56) |
483 | 363 | .84 1.02 (0.82–1.27) |
||
| Negative | 131 | 118 | 14.9 | 213 | 159 | 44.9 | ||
| Positive | 153 | 147 | 13.2 | 270 | 204 | 44.4 | ||
| IgG for EBV | 284 | 265 | .28 0.78 (0.49–1.23) |
483 | 363 | .056 0.67 (0.45–1.01) |
||
| Negative | 22 | 21 | 13.0 | 35 | 27 | 40.5 | ||
| Positive | 262 | 244 | 14.3 | 448 | 336 | 44.9 | ||
| IgG for HSV | 282 | 263 | .069 1.30 (0.98–1.72) |
380 | 360 | .64 0.94 (0.73–1.21) |
||
| Negative | 79 | 72 | 17.1 | 125 | 88 | 83.0 | ||
| Positive | 203 | 191 | 13.7 | 355 | 272 | 37.3 |
aHR adjusted for age, sex, race (white/nonwhite), series, and surgery (resection/biopsy only). Models include stratification by tumor grade. Hazard ratio for seropositive individuals.